Literature DB >> 10552233

The rise and fall of tolcapone.

C Colosimo1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552233     DOI: 10.1007/s004150050477

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  Tolcapone suppresses ethanol intake in alcohol-preferring rats performing a novel cued access protocol.

Authors:  Aqilah M McCane; Cristine L Czachowski; Christopher C Lapish
Journal:  Alcohol Clin Exp Res       Date:  2014-09       Impact factor: 3.455

2.  High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.

Authors:  Anuradha Balasubramanian; Mark Manzano; Tadahisa Teramoto; Rajendra Pilankatta; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2016-08-15       Impact factor: 5.970

3.  Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Jasper Dingemanse; Carsten Meyerhoff; Jan Schadrack
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 4.  Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Authors:  Nuno Borges
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.

Authors:  Ádám Annus; László Vécsei
Journal:  Drug Des Devel Ther       Date:  2017-01-09       Impact factor: 4.162

Review 6.  Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.

Authors:  Daniel D Truong
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

Review 7.  Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Authors:  K H O Deane; S Spieker; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

8.  COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Authors:  Angelo Antonini; Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Marco Onofrj; Mario Zappia; Aldo Quattrone
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.